On February 26, 2023, Nano Body Life Science and Technology Co., Ltd. (hereinafter referred to as 'NBLST'), together with Hubei TopGene Biotechnology Co., Ltd. (hereinafter referred to as 'TopGene Biotech'), celebrated their relocation. The headquarters offices of both companies were smoothly relocated to the main building of the Wuhan Institute of Industrial Innovation and Development in the East Lake New Technology Development Zone of Wuhan City (hereinafter referred to as 'WHIIID').

　As one of the first companies to settle in WHIIID, Li Xiling, the director of WHIIID, warmly welcomed the relocation of Nano Body Life Science and Technology Co., Ltd., and Hubei TopGene Biotechnology Co., Ltd. She expressed that the simultaneous relocation of both companies signifies the full-speed development stage of WHIIID's nanobody industry platform, innovative drug discovery and non-clinical evaluation service platform, and antiviral drug research institute

　Action reinforces knowledge, and profound understanding facilitates further action.' Ma Chunhui, the General Manager of Nano Body Life Science and Technology, expressed that as the earliest biopharmaceutical company to invest and settle in WHIIID, Nano Body Life Science and Technology will leverage innovative resources such as cutting-edge technology, project management, market demand, and capital elements. It aims to vigorously develop a 'reservoir' for talent, technology, and capital in the field of biomedicine, becoming a new model for WHIIID's exploration and construction of an innovation system.

　Those who seek the height of a tree must strengthen its roots; those who aspire to a distant flow must dig deep into its sources.' This relocation marks an important milestone in the development of TopGene Biotech, representing a new platform for the company's resurgence and also a crucial step in its strategic adjustment. Chairman Ren Xidong stated that today's settlement signifies the innovative community jointly built by multiple parties stepping onto a new level and ascending to new heights.

Though the road is long and arduous, with perseverance, success is within reach; as long as we keep moving forward, the future holds promise. The new office environment and facilities symbolize a new chapter for the Nanobo team. Looking back, we are filled with joy and inspiration by our past achievements; looking ahead, we are motivated to overcome new challenges. On the occasion of our headquarters' relocation, we extend our heartfelt gratitude to the numerous scientists who have long supported and recognized our company, as well as to our partners from across the country with whom we have maintained long-term collaborations. May we progress and prosper together.

About WHIIID:

The Wuhan Institute of Industrial Innovation and Development (WHIIID) is a new research institution hosted by the Wuhan Municipal Government. It is a non-institutional, non-officially specified organization, and a legal entity, led by a board of directors under the leadership of the president. It operates with enterprise management and market-oriented operation. Adhering to the philosophy of 'development as the top priority, talents as the primary resource, and innovation as the driving force,' WHIIID focuses on removing all ideological and institutional barriers hindering technological innovation, gathers high-quality innovative resources from home and abroad, and aims to create the most attractive platform for innovation, creation, and wealth.

About TopGene Biotech:

Hubei TopGene Biotechnology Co., Ltd. was established in 2009, headquartered in the Wuhan Institute of Industrial Innovation and Development in the Donghu High-tech Zone of Wuhan City. It is a high-tech enterprise specializing in large animal experiments and new drug research and evaluation. Adhering to the core value of 'serving medical innovation and dedicating to life and health,' TopGene Biotech has successfully established six technical platforms, including the breeding of non-human primates, human disease animal models, drug toxicity research and safety evaluation, pharmacokinetics and pharmacodynamics research and evaluation, molecular imaging technology, and biological analysis. The company is the only private GLP institution in Hubei Province and has passed CNAS certification and international AAALAC certification at one time.

About NBLST:

Wuhan Nano Body Life Science and Technology Co., Ltd. was established with strong support from the Wuhan Municipal Government and is jointly established by the Wuhan Institute of Industrial Innovation and Development, Guangzhou Bioisland Laboratory, and the School of Life Science and Technology of Huazhong University of Science and Technology. The company has independently developed a high-throughput antibody screening and detection platform and a breeding base for camels that meet experimental animal standards, providing customized and labeled modification services for nanobodies. With the Wuhan Nanobody Research Center at WHIIID as its technical core, the company will vigorously improve the Wuhan Nanobody Industry Development Project, in line with Wuhan's policy of 'vigorous development of the biomedical and medical device industries, planning to develop into trillion-yuan pillar industries.' This project will rely on solid scientific research and high-quality products to overcome the 'bottleneck' key core technology in the domestic antibody field, break the monopoly of high-quality foreign antibody products, establish standards for nanobody industry products and services, drive the standardized, large-scale, and high-level development of China's antibody industry, seize the commanding heights of the global antibody industry with nanobody products, drive the replacement of traditional antibodies with nanobodies in various scientific research and diagnostic fields, and promote the high-quality development of Wuhan's upstream and downstream industries based on nanobodies nationwide.